SEARCH:   Advanced

Blood, 1 October 2008, Vol. 112, No. 7, pp. 2687-2693. Prepublished online as a Blood First Edition Paper on July 14, 2008; DOI 10.1182/blood-2008-03-147025. This Article Full Text Full Text (PDF) Supplemental Appendix All Versions of this Article: blood-2008-03-147025v1 112/7/2687    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Geisler, C. H. Articles by Elonen, E. Search for Related Content PubMed PubMed Citation Articles by Geisler, C. H. Articles by Elonen, E. Related Collections Free Research Articles Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo–purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group Christian H. Geisler1, Arne Kolstad2, Anna Laurell3, Niels S. Andersen1, Lone B. Pedersen1, Mats Jerkeman4, Mikael Eriksson4, Marie Nordström5, Eva Kimby5, Anne Marie Boesen6, Outi Kuittinen7, Grete F. Lauritzsen2, Herman Nilsson-Ehle8, Elisabeth Ralfkiær1, Måns Åkerman4, Mats Ehinger4, Christer Sundström3, Ruth Langholm2, Jan Delabie2, Marja-Liisa Karjalainen-Lindsberg9, Peter Brown1, Erkki Elonen9, and for the Nordic Lymphoma Group 1 Rigshospitalet, Copenhagen, Denmark; 2 Norwegian Radium Hospital, Oslo, Norway; 3 Uppsala University Hospital, Uppsala, Sweden; 4 Lund University Hospital, Lund, Sweden; 5 Karolinska Institute, Stockholm, Sweden; 6 Aarhus University Hospital, Aarhus, Denmark; 7 Oulu University Hospital, Oulu, Finland; 8 Sahlgrenska Hospital, Gothenburg, Sweden; and 9 Helsinki University Central Hospital, Helsinki, Finland Mantle cell lymphoma (MCL) is considered incurable. Intensive immunochemotherapy with stem cell support has not been tested in large, prospective series. In the 2nd Nordic MCL trial, we treated 160 consecutive, untreated patients younger than 66 years in a phase 2 protocol with dose-intensified induction immunochemotherapy with rituximab (R) + cyclophosphamide, vincristine, doxorubicin, prednisone (maxi-CHOP), alternating with R + high-dose cytarabine. Responders received high-dose chemotherapy with BEAM or BEAC (carmustine, etoposide, cytarabine, and melphalan/cyclophosphamide) with R-in vivo purged autologous stem cell support. Overall and complete response was achieved in 96% and 54%, respectively. The 6-year overall, event-free, and progression-free survival were 70%, 56%, and 66%, respectively, with no relapses occurring after 5 years. Multivariate analysis showed Ki-67 to be the sole independent predictor of event-free survival. The nonrelapse mortality was 5%. The majority of stem cell products and patients assessed with polymerase chain reaction (PCR) after transplantation were negative. Compared with our historical control, the Nordic MCL-1 trial, the event-free, overall, and progression-free survival, the duration of molecular remission, and the proportion of PCR-negative stem cell products were significantly increased (P < .001). Intensive immunochemotherapy with in vivo purged stem cell support can lead to long-term progression-free survival of MCL and perhaps cure. Registered at www.isrctn.org as #ISRCTN 87866680. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: Y. L. Kasamon, R. J. Jones, R. A. Brodsky, E. J. Fuchs, W. Matsui, L. Luznik, J. D. Powell, A. L. Blackford, A. Goodrich, C. D. Gocke, et al. Immunologic recovery following autologous stem-cell transplantation with pre- and posttransplantation rituximab for low-grade or mantle cell lymphoma Ann. Onc., October 30, 2009; (2009) mdp484v1. [Abstract] [Full Text] [PDF] N. S. Andersen, L. B. Pedersen, A. Laurell, E. Elonen, A. Kolstad, A. M. Boesen, L. M. Pedersen, G. F. Lauritzsen, R. Ekanger, H. Nilsson-Ehle, et al. Pre-Emptive Treatment With Rituximab of Molecular Relapse After Autologous Stem Cell Transplantation in Mantle Cell Lymphoma J. Clin. Oncol., September 10, 2009; 27(26): 4365 - 4370. [Abstract] [Full Text] [PDF] A. J. Moskowitz and C. H. Moskowitz Controversies in the Treatment of Lymphoma with Autologous Transplantation Oncologist, September 1, 2009; 14(9): 921 - 929. [Abstract] [Full Text] [PDF] M. Ghielmini and E. Zucca How I treat mantle cell lymphoma Blood, August 20, 2009; 114(8): 1469 - 1476. [Abstract] [Full Text] [PDF] K. Gustafsson, B. Sander, J. Bielawski, Y. A. Hannun, and J. Flygare Potentiation of Cannabinoid-Induced Cytotoxicity in Mantle Cell Lymphoma through Modulation of Ceramide Metabolism Mol. Cancer Res., July 1, 2009; 7(7): 1086 - 1098. [Abstract] [Full Text] [PDF] C. S. Tam, R. Bassett, C. Ledesma, M. Korbling, A. Alousi, C. Hosing, P. Kebraei, R. Harrell, G. Rondon, S. A. Giralt, et al. Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma Blood, April 30, 2009; 113(18): 4144 - 4152. [Abstract] [Full Text] [PDF] Aggressive Therapy for Mantle Cell Lymphoma Journal Watch Oncology and Hematology, September 23, 2008; 2008(923): 1 - 1. [Full Text]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020